<?xml version="1.0" encoding="UTF-8"?>
<results title="funder">
 <result pre="on G/P from Austria. The results may serve as a" exact="basis" post="for further HCV-microelimination strategies. Patients and methods All DAA-naïve"/>
 <result pre="OST program, receiving their OST on a daily or weekly" exact="basis" post="at a pharmacy or a low-threshold facility. It is"/>
 <result pre="pharmacy or at the Ambulatorium Suchthilfe Wien on a once-daily" exact="basis" post="(i.e. from Monday to Saturday and only the doses"/>
 <result pre="in a few cases, on a once-weekly, twice-weekly or thrice-weekly" exact="basis" post="(&quot;directly observed therapy group&quot;). Patients without a history of"/>
 <result pre="live in Vienna and are included in the nationwide OST" exact="program" post="were treated according to the DOT-concept. The outcome of"/>
 <result pre="did not attend their OST distribution facility on a daily" exact="basis" post="but only once, twice or thrice a week and"/>
 <result pre="imprisonment and unstable socioeconomic factors. The inclusion in an OST" exact="program" post="was considered a positive prognostic factor and was used"/>
 <result pre="are planning to introduce a peer-based HCV screening and treatment" exact="program" post="for PWIDs in Vienna. The project shall focus on"/>
 <result pre="fibrosis assessment and HCV treatment initiation within a systematic screening" exact="program" post="in HIV/HCV coinfected patients. Wien Klin Wochenschr. 20182;130(3–4):105–14. 10.1007/s00508-017-1231-x28744597"/>
</results>
